Home › RLT targets by cancer › Glioma
Radioligand therapy · Glioma

Radioligand Therapy Targets in Glioma

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in glioma (including glioblastoma (GBM)). 3,925 show detectable protein staining. Established and emerging radioligand targets expressed in glioma include EGFR, HER3 (ERBB3), ITGAV and B7-H3 (CD276). Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own glioma program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank glioma targets free

Established and emerging radioligand targets in glioma

Targets already pursued with radioligands or other targeted modalities that show protein expression in glioma:

TargetIHC in glioma% positiveInternalizes
EGFRHigh (0.81)92%yes
HER3 (ERBB3)High (0.75)100%yes
ITGAVHigh (0.72)100%—
B7-H3 (CD276)High (0.61)100%—
STEAP2Medium (0.47)83%—
c-MET (MET)Medium (0.42)100%yes
TMEFF2Medium (0.25)50%—
SSTR2Medium (0.21)46%yes
Nectin-4 (NECTIN4)Low (0.08)17%no
FAPLow (0.08)17%yes
Claudin 18.2 (CLDN18)Low (0.06)8%uncertain
KITLow (0.03)8%no

Top cell-surface targets for glioma radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in glioma% positiveInternalizesClinical stage
1S1PR1
sphingosine-1-phosphate receptor 1
High (0.86)100%yesFDA-Approved
2EGFR
epidermal growth factor receptor
High (0.81)92%yesFDA-Approved
3PTPRB
protein tyrosine phosphatase receptor type B
High (0.88)100%yesClinical
4HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.75)100%yesFDA-Approved
5IGF1R
insulin like growth factor 1 receptor
High (0.72)100%yesFDA-Approved
6AMFR
autocrine motility factor receptor
High (0.97)100%yesDiscovery
7GPR139
G protein-coupled receptor 139
High (0.89)100%yesDiscovery
8PTGER4
prostaglandin E receptor 4
High (0.93)100%uncertainFDA-Approved
9NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.75)100%uncertainFDA-Approved
10PTPN13
protein tyrosine phosphatase non-receptor type 13
High (0.83)100%yesDiscovery
11MAOB
monoamine oxidase B
High (0.85)100%—FDA-Approved
12NOTCH1
notch receptor 1
High (0.64)100%yesClinical
13c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
Medium (0.42)100%yesFDA-Approved
14TREM1
triggering receptor expressed on myeloid cells 1
High (0.77)100%uncertainClinical
15CHRNA7
cholinergic receptor nicotinic alpha 7 subunit
High (0.63)100%yesClinical
16IL1R2
interleukin 1 receptor type 2
High (0.58)100%yesDiscovery
17GLRB
glycine receptor beta
High (0.83)100%uncertainFDA-Approved
18EPHA3
EPH receptor A3
Medium (0.47)100%yesFDA-Approved
19RNF43
ring finger protein 43
High (0.97)100%—Discovery
20IRAK4
interleukin 1 receptor associated kinase 4
High (0.58)100%yesClinical
21MMP10
matrix metallopeptidase 10
High (0.97)100%—Discovery
22NSD1
nuclear receptor binding SET domain protein 1
High (1.00)100%uncertainDiscovery
23FGFR1
fibroblast growth factor receptor 1
Medium (0.42)92%yesFDA-Approved
24HMGB1
high mobility group box 1
High (1.00)100%—Clinical
25LIFR
LIF receptor subunit alpha
High (0.69)92%yesDiscovery

Internalizing receptors in glioma

Targets expressed in glioma that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

S1PR1 · EGFR · PTPRB · HER3 (ERBB3) · IGF1R · AMFR · GPR139 · PTPN13 · NOTCH1 · c-MET (MET) · CHRNA7 · IL1R2

Glioma targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in glioma. Clinical precedent lowers development risk but usually means more competition:

S1PR1 · EGFR · PTPRB · HER3 (ERBB3) · IGF1R · PTGER4 · NR3C2 · MAOB · NOTCH1 · c-MET (MET) · TREM1 · CHRNA7

How these glioma targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in glioma, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank glioma targets against your own criteria: isotope, organ limits, novelty.

Run a free glioma analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist glioma targets for your program · 5 free analyses, no card Rank glioma targets free